Valneva announced the initiation of a Phase 1/2 clinical study for its inactivated, adjuvanted COVID-19 vaccine candidate, VLA2001.
Valneva Initiates Phase 1/2 Clinical Study of Inactivated, Adjuvanted COVID-19 Vaccine Candidate
Toggle Navigation
- ResearchBack
- Research at Vienna BioCenter
- Research Areas
- Research Groups
- Key Discoveries
- Recent Research Highlights
- Vienna Covid-19 Detection InitiativeBack
- Research Entities
- Biotech Companies
- Facilities
- Events
- Career
- Facilities
Back- Companies
Back- Companies at Vienna BioCenter
- Biotech CompaniesBack
- a:head
- Ablevia Biotech
- ACCANIS Biotech
- Aelian Biotechnology
- Affiris
- Akribes
- Allcyte
- Apeiron Biologics
- Ares Genetics
- Austrianni
- Bird-C
- CALYXHA Biotechnologies
- ChanPharm
- EUCODIS Bioscience
- Eveliqure
- Evercyte
- G.ST Antivirals
- Haplogen
- Hookipa Pharma
- JLP Health
- Lexogen
- Miti Biosystems
- OncoOne
- Origimm
- PhagoMed
- Phenaris
- Pregenerate
- Proxygen
- QUANTRO Therapeutics
- SCARLETRED
- TAmiRNA
- Thermo Fisher Scientific
- Valneva
- X4 Pharmaceuticals
- Service Companies
- Business Incubators
- Scientific AssociationBack
- Education
- Career